Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich's Genous(TM) Bio-engineered R... ( SAN FRANCISCO Sept. 22 /-...)

HOME >> BIOLOGY >> TECHNOLOGY

Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)

Date:9/22/2009

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- OrbusNeich today announced that the final 12-month clinical data from the global e-HEALING clinical study showed that the company's Genous Bio-engineered R stent is safe and effective in real world use, including in the treatment of patients with diabetes mellitus.

The study evaluated 4,987 of the 4,996 enrolled patients and found a target vessel failure (TVF) rate of 8.1 percent at 12 months with a follow-up rate of 92 percent, a target lesion revascularization (TLR) rate of 4.4 percent, a major adverse cardiac events (MACE) rate of 7.7 percent, a subacute thrombosis (SAT) rate of 0.5 percent and a late stent thrombosis (LST) of 0.3 percent. The combined SAT and late thrombosis rate of 0.8 percent was per protocol. Per Academic Research Consortium (ARC) definition, the definite and probable SAT and late thrombosis rate is 1.0 percent. The data were presented by Professor Robbert de Winter, M.D., Ph.D., of the Academic Medical Center in Amsterdam at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2009, in San Francisco.

"The excellent study design, electronic data capture and monitoring as well as comprehensive data management resulted in robust data for the e-HEALING clinical study, which further supports the efficacy and safety of the Genous Bio-engineered R stent," said de Winter, a co-principal investigator of the study. "We are especially pleased to see positive results in certain subsets of patients, such as diabetic patients, which often present as challenging cases with an expected higher incidence of in-stent-restenosis."

Twenty five percent of the patients in the study had diabetes mellitus. In a poster presentation, also at TCT 2009, de Winter and colleagues reported data from an analysis of this subset of the e-HEALING study. The 12-month follow-up from these 1,243 patients with diabetes mellitu
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Cadient Group Selected as Finalist in Medical Marketing & Media Awards
2. Prix Galien USA Announces 2009 Final Candidates
3. Quest Diagnostics Announces Final Tender Offer Results
4. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
5. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
8. Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006
9. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
10. University of Maryland Announces Finalists for $75K Business Plan Competition
11. Impact Systems' Compliance-in-a-Box™ Video is Announced as "Be the Buzz of Bio" Contest Finalist

Post Your Comments:

(Date:12/14/2009)... 14 Array BioPharma Inc. (Nasdaq: ... today announced that they entered into an agreement ... glucokinase activator program, including ARRY-403, currently being tested ... with Type 2 diabetes. ,, Under ... an upfront payment of $60 million and additional ...

(Date:12/14/2009)... Dec. 14 Boston Scientific Corporation (NYSE: ... public offering of $2 billion aggregate principal amount of ... The public offering consists of $850 million of ... 6.00 percent notes due January 2020 and $300 million ... Scientific plans to use the net proceeds for general ...

(Date:12/14/2009)... BRUSSELS, December 14 , ... Lifestyles of,Women With Rheumatoid Arthritis in Seven Major Industrialized Countries ... living with rheumatoid arthritis say their disease, ... - Women living with rheumatoid arthritis find shopping ... writing cards and wrapping presents most, ...

(Date:12/11/2009)... have observed the "hot electron" effect in a solar ... elusive charges using ultra-thin solar cells, opening a potential ... in the current online edition of Applied Physics ... cells, it generates free electrons in a range of ... the electrons must reach the bottom of the conduction ...

Breaking Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2 Array BioPharma and Amgen Partner in Type 2 Diabetes 3 Array BioPharma and Amgen Partner in Type 2 Diabetes 4 Array BioPharma and Amgen Partner in Type 2 Diabetes 5 Array BioPharma and Amgen Partner in Type 2 Diabetes 6 Array BioPharma and Amgen Partner in Type 2 Diabetes 7 Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2 Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3 Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2 Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3 Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4 Elusive 'hot' electrons captured in ultra-thin solar cells 2

[0] Array BioPharma and Amgen Partner in Type 2 Diabetes [0] Boston Scientific Announces Completion of $2 Billion Senior Notes Offering [0] Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas [0] Elusive 'hot' electrons captured in ultra-thin solar cells

... 23andMe , Inc., an industry leader in personal ... company dedicated to the development of treatments for rare ... Davos, Switzerland, that they are collaborating to advance research ... the companies to the World Economic Forum, where they ...

... Canada,s National Institute for Nanotechnology and the University of ... individual electrons, a development that suddenly brings quantum dot-based ... of silicon and measuring less than one nanometre in ... , Quantum dots have extraordinary electronic properties, ...

... PUBLISHED BY UNIVERSAL , NETTLETON, Miss., Jan. 27 ... that certain unauthorized inaccurate information is being published ... website, potentially other websites and publications, and an ... company has found errors in statements concerning the ...

Other Biology Technology:23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases 2 23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases 3 Smallest ever quantum dots bring real world applications closer 2

23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases Smallest ever quantum dots bring real world applications closer Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet

(Date:12/15/2009)... HERNDON, Va., Dec. 15 The PTR Group, ... today announced that it has agreed to sponsor three ... US FIRST Robotics Competition ( http://usfirst.org ). ... high school teams in three different states. The ... in Rockwall, TX, and James Madison HS in Vienna, ...

(Date:12/14/2009)... -- (Dec. 14, 2009) -- Researchers at Rice University ... single nanoparticle that can be tracked in real time ... tags them with a fluorescent dye and kills them ... first examples from a growing field called "theranostics" that ... diseases in a single procedure. , The research is ...

(Date:12/14/2009)... promoted as a clean-burning, renewable fuel that could help ... problems caused by ozone, compared with gasoline, especially in ... researchers. , Ozone production from both gasoline and ... 85 percent ethanol, is greater in warm sunny weather ... winter, because heat and sunlight contribute to ozone formation. ...

[0] The PTR Group Announces Financial and Technical Support to US FIRST Robotics Competition Teams [0] Tracking new cancer-killing particles with MRI [0] Ethanol-powered vehicles generate more ozone than gas-powered ones

... hepatitis C virus (HCV) are at an increased risk ... according to a study published in the May 8, ... Association. Researchers from the National Cancer Institute (NCI), ... College of Medicine, found that HCV infection increased the ...

... certain neurodegenerative diseases, such as mad cow disease or ... of infectious protein called a prion. Remarkably, in recent ... beneficial roles in biology, and prions even may act ... , But although prions have received a great deal ...

... The Fumanya site, in the Bergueda region of central Catalonia, ... to the tracks to examine them. , In the years ... the elements, and as a result are severely weathered and ... even more difficult, the tracks are imprinted into near-vertical rock ...

Other Biology News:Risk of lymphoma increases with hepatitis C virus infection 2 Scientists identify prion's infectious secret 2 Scientists identify prion's infectious secret 3 Diminishing dinosaur steps saved by laser and laptop 2 Diminishing dinosaur steps saved by laser and laptop 3

Risk of lymphoma increases with hepatitis C virus infection Scientists identify prion's infectious secret Diminishing dinosaur steps saved by laser and laptop

... (PI) is a fluorescent nucleic acid dye ... As a nuclear counterstain, propidium iodide ... in color. The fluorescent red color ... fluorochromes such as FITC, Cy2 or AMCA. ...

... simultaneous dual parameter assay for mitochondrial ... activity. Active caspases are detected by ... which are cell-permeable, non-cytotoxic and bind ... the cells. At the same time ...

... DMEM and harvested at the log phase of ... in their native forms, cells were fixed in ... 12-well (5 mm) adhesive coated slide, with each ... and to minimize background staining. Each well ...

... The CopyControl™ vector can be induced ... These vectors provide the stability of single-copy ... cosmids or other cloning vectors. The kits ... (ligation reagents, insert size screening system) necessary ...

Biology Products:

Propidium Iodide from KPL Mito Casp from BACHEM L1210 cell line slides ( mouse: lymphocytic leukemia ) from GeneTex CopyControl BAC Cloning Kit (BamH I) from EPICENTRE Biotechnologies

Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich's Genous(TM) Bio-engineered R...( SAN FRANCISCO Sept. 22 /-...)